- Home
- / Edwards Lifesciences
Edwards Lifesciences
Stock Price
$72.9
2023-09-18
Market Capitalization
$44.3 B
2023-09-18
Revenue
$5.4 B
FY, 2022
Edwards Lifesciences Summary
Company Summary
- Overview
- Edwards Lifesciences is a company operating as a global provider of patient-focused medical solutions for structural heart disease and critical care monitoring. The company develops heart valve therapies and manufactures heart valve systems and repair products used to replace or repair diseased or defective heart valves. It also offers hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.
- Type
- Public
- Status
- Active
- Founded
- 1958
- HQ
- Irvine, CA, US | view all locations
- Website
- http://www.edwards.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Michael A. Mussallem, Chairman and Chief Executive Officer
Todd J. Brinton, Corporate Vice President, Advanced Technology, Chief Scientific Officer
Daveen Chopra, Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies
Operating MetricsView all
Patents and Patent Applications
4.7K
20.5%
FY, 2019
Manufacturing Facilities
7
FY, 2020
Countries
100
FY, 2020
LocationsView all
41 locations detected
Irvine, CA HQ
United States
1 Edwards Way
Draper, UT
United States
12050 Lone Peak Pkwy
Washington, DC
United States
601 13th St NW #350
Macquarie Park, NSW
Australia
40 Talavera Rd
Wien, Wien
Austria
Vorgartenstraße 206C
Dilbeek, Vlaanderen
Belgium
Pontbeekstraat 4
Edwards Lifesciences Financials
Summary Financials
- Revenue (Q2, 2023)
- $1.5B
- Gross profit (Q2, 2023)
- $1.2B
- Net income (Q2, 2023)
- $305.5M
- Cash (Q2, 2023)
- $1.0B
- EBIT (Q2, 2023)
- $327.2M
- Enterprise value
- $43.9B